Alten Calsoft Labs looks to extend U.S. reach

Alten Group Deputy CEO Gerald Attia

IT and product engineering company Alten Calsoft Labs has acquired the niche U.S. CRO PVR Technologies as it looks to delve more deeply into the U.S. life sciences world.

The Bangalore-based company--itself a subsidiary of the Parisian Alten Group--currently works with healthcare and life science companies to help with their product engineering, IT and digital initiatives.

But with this latest buy, the company is now looking to broaden its reach into the service sector for the industry, as well as into the lucrative U.S. market. Financial details were not disclosed.

PA-based PVR Technologies, founded in 2006, currently runs services for a number of companies in the biotech, pharma, medical device and clinical research space, with a focus on biostatistics, SAS and R-Programming and data management for the industry in the U.S.

"Inorganic growth is a part of our strategy and this acquisition strengthens our healthcare story in the U.S. PVR Technologies is an ideal fit for Alten Calsoft Labs with the vision of creating our expertise in the area of statistics, business intelligence, analysis and reporting," explained Gerald Attia, deputy CEO of the Alten Group.

Ramandeep Singh, CEO at Alten Calsoft Labs, added: "By acquiring one of the pioneer CRO services company like PVR Technologies, we are poised to grow our healthcare and life sciences business faster. We welcome over 200 statistical minds that will enable us to achieve a stronger presence in the US region and will accelerate our drive in the healthcare and life sciences markets."

- check out the release

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.